Puma Biotechnology News

Puma Biotechnology Aktie VALOR 18238887 / ISIN US74587V1070

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

04.10.23	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
21.09.23	Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer (Businesswire)
31.08.23	Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Businesswire)
08.08.23	Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer (Businesswire)
03.08.23	Puma Biotechnology Reports Second Quarter Financial Results (Businesswire)
20.07.23	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results (Businesswire)
06.06.23	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.05.23	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
04.05.23	Puma Biotechnology Reports First Quarter Financial Results (Businesswire)
20.04.23	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results (Businesswire)
11.04.23	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
14.03.23	Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology (Businesswire)
03.03.23	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.03.23	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Businesswire)
28.02.23	Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference (Businesswire)
16.02.23	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results (Businesswire)
07.02.23	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
01.02.23	Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	178.95	0.51 %	K V
ABB	60.88	0.40 %	K V
Nestle	75.20	0.28 %	K V
Logitech Intl	77.10	0.16 %	K V
CieFinRichemont	175.60	0.11 %	K V
Holcim	78.16	-1.49 %	K V
Swiss Life Hldg	869.80	-2.03 %	K V
Part Grp Hldg	1’014.50	-2.31 %	K V
Sika	149.10	-9.50 %	K V